We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

New Pathway for COPD Biomarker Development

New Pathway for COPD Biomarker Development

New Pathway for COPD Biomarker Development

New Pathway for COPD Biomarker Development

Read time:

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "New Pathway for COPD Biomarker Development"

First Name*
Last Name*
Email Address*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy


A new study published in the International Journal of Molecular Sciences has demonstrated the potential of multi-lipid profiling to support future biomarker development for Chronic Obstructive Pulmonary Disease (COPD).1 Combining lipidomic profiling with computational network biology analyses, researchers were able to build a comprehensive and quantitative picture of the lipidome that is capable of distinguishing cigarette smokers from non-smokers, with improved separation of smokers that were symptomatic of mild to moderate COPD. 

“This study has clearly demonstrated that there are many lipids, beyond those conventionally measured in the clinic, that are responsive in the section of society most at risk of COPD, i.e. cigarette smokers,” said Dr Björn Titz, Computational Biology, Philip Morris International (PMI). “Lipidomic information relating to smoke exposure and COPD has until now been relatively sparse. At the same time, markers discovered by lipidomics for other conditions are starting to make their way into the clinic. As such, this study should be highly relevant to scientists working in COPD from the point of view of biomarker development or personalized medicine.” 

The study was designed to identify a biomarker, or panel of biomarkers, suitable for the differentiation of four groups: smokers with mild to moderate COPD, healthy smokers, individuals who have never smoked, and individuals who have quit smoking for a year or more. Males and females between the ages of 41 and 70 years took part. A combination of four mass spectrometry based platforms were used for the purpose of lipidome analysis, monitoring a total of 26 different lipid classes. The approach allowed for the detection and quantification of diverse lipids over a wide concentration range.

Leveraging a network biology analysis approach, the authors identified three main lipidomic trends between smokers and non-smokers: a general increase in glycerophospholipids (the main component of all biological membranes, e.g. cell membranes), changes in fatty acid desaturation (a decrease in poly-unsaturated fatty acids, an increase in mono-unsaturated fatty acids), and an imbalance in eicosanoids (signaling molecules that exert complex control over many bodily systems). 

These effects often appeared amplified and more significant in the group of smokers with COPD in comparison to the group of smokers without COPD. However, the COPD group was also associated with a higher cumulative smoking exposure than the healthy smoking group, so it remains unclear which effects are more closely linked to COPD, rather than being the results of more extensive cigarette smoke exposure. This suggests that the future study of former smokers with COPD may help to identify effects that are more specifically related to COPD itself, rather than cigarette smoking.

“This study has yielded important new insights into the complex interplay between cigarette smoke exposure, lung disease and alterations in lipid profiles,” said Dr Julia Hoeng, Director of Systems Toxicology, Biological Systems Research, PMI. “In addition, it identifies new avenues for research in the ongoing quest to identify a robust biomarker for COPD and to benefit from all that such a discovery would entail, from diagnostics, to drug discovery, to personalized medicine.”

1. Titz B, et al. 2016. Alterations in serum polyunsaturated fatty acids and eicosanoids in patients with mild to moderate Chronic Obstructive Pulmonary Disease (COPD). Int J Mol Sci. 20;17(9). pii: E1583. Doi: 10.3390/ijms17091583